LSE:AZNPharmaceuticals
AstraZeneca Adds Regulatory Wins As Valuation And Growth Prospects Scrutinised
Health Canada approves Koselugo (selumetinib) for adults with neurofibromatosis type 1, expanding AstraZeneca’s rare disease reach in Canada.
The US FDA grants Priority Review to ENHERTU for early stage HER2 positive breast cancer, targeting a new setting in AstraZeneca’s oncology franchise.
Both decisions mark fresh regulatory momentum for AstraZeneca (LSE:AZN) across rare disease and oncology portfolios.
For you as an investor, these updates add additional context to AstraZeneca’s mix of...